Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
In this editorial, we shed light on the key advances made in migraine genetics, their neurobiology and what the future might hold for the field.
A drug belonging to a new generation of acute migraine headache treatments, termed rimegepant, has been demonstrated to eliminate pain and reduce bothersome symptoms.
Researchers have determined that CGRP exhibits pain effects in a sex-specific manner. Understanding these sex-specific differences could help us understand why migraines are three-times more common in women than in men.
Researchers have identified natural killer cells as a potential therapeutic target for the treatment of neuropathic pain. The immune cells can selectively degenerate axons, allowing repair of damaged nerves.
Researchers have developed an application that could detect when an opioid overdose has taken place; potentially leading to a greater number of individuals receiving medical help in this situation.
Scientists have created a vaccine containing monoclonal antibodies that are effective against several synthetic opioids, including carfentanil.
Spinal cord stimulation and physical therapy have been reported to help a man, paralyzed since 2013, regain his ability to stand and walk with assistance.
Researchers have revealed that tetrahydrocannabinol, found in marijuana, may reduce the number of connections between areas of the brain that process pain; this could lead to pain relief in individuals with chronic radicular nerve pain.
In this NCTalks podcast, Lauren Pulling speaks to Irene Tracey to hear more about her talk on imaging perception and lessons from pain, analgesia and anesthesia.